The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 24, 2025

Filed:

Sep. 17, 2022
Applicant:

Max-delbrück-centrum Für Molekulare Medizin (Mdc) Berlin-buch, Berlin, DE;

Inventors:

Thomas Blankenstein, Berlin, DE;

Matthias Obenaus, Berlin, DE;

Catarina Leitão, Lisbon, PT;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/725 (2006.01); C07K 14/705 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); G01N 33/574 (2006.01); C12N 15/62 (2006.01);
U.S. Cl.
CPC ...
C07K 14/7051 (2013.01); C07K 14/70503 (2013.01); C07K 16/2803 (2013.01); C07K 16/30 (2013.01); G01N 33/57484 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C12N 15/62 (2013.01); G01N 2333/705 (2013.01);
Abstract

The present invention pertains to novel high avidity antigen recognizing constructs, such as antibodies or T cell receptors, which specifically bind to the melanoma associated antigen (MAGE) A1. The constructs of the invention are particularly useful for the diagnosis, prevention or therapy of tumorous diseases which are characterized by the specific expression of the MAGE-A1 antigen. Furthermore provided are nucleic acids, vectors and host cells—such as CD4 or CD8 positive T cells—which encode, comprise or present the antigen recognizing constructs of the invention. The invention thus provides new approaches for immune therapy, specifically adoptive T cell therapy, for treating cancer.


Find Patent Forward Citations

Loading…